Small fiber neuropathy
Acta Neurologica Scandinavica · 2022-05 · 145 (5) · 493-503
DOI: 10.1111/ane.13591 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Acta Neurologica Scandinavica, online erschienen am 07.02.2022. Verfasst von Josef Finsterer und 1 weiteren Autor:innen. Beteiligte Einrichtung: Neurology & Neurophysiology Center, Vienna, Austria. Hauptthemen laut MEDLINE: Peripheral Nervous System Diseases, Small Fiber Neuropathy. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 80 Literaturangaben.
Abstract (Originalsprache)
Small fiber neuropathy (SFN) is a peripheral nervous system disease due to affection of A-delta or C-fibers in a proximal, distal, or diffuse distribution. Selective SFN (without large fiber affection) manifests with pain, sensory disturbances, or autonomic dysfunction. Though uniform diagnostic criteria are unavailable, most of them request typical clinical features and reduced intra-epidermal nerve fiber density on proximal or distal skin biopsy. Little consensus has been reached about the treatment of SFN, why this narrative review aims at summarizing and discussing treatment options for SFN. Treatment of SFN can be classified as symptomatic, pathophysiologic, or causal. Prerequisites for treating SFN are an established diagnosis, knowledge about the symptoms and signs, and the etiology. Pain usually responds to oral/intravenous pain killers, antidepressants, anti-seizure drugs, or topical, transdermal specifications. Some of the autonomic disturbances respond favorably to symptomatic treatment. SFN related to Fabry disease or hATTR are accessible to pathogenesis-related therapy. Immune-mediated SFN responds to immunosuppression or immune-modulation. Several of the secondary SFNs respond to causal treatment of the underlying disorder. In conclusion, treatment of SFN relies on a multimodal concept and includes causative, pathophysiologic, and symptomatic measures. It strongly depends on the clinical presentation, diagnosis, and etiology, why it is crucial before initiation of treatment to fix the diagnosis and etiology. Due to the heterogeneous clinical presentation and multi-causality, treatment of SFN should be individualized with the goal of controlling the underlying cause, alleviating pain, and optimizing functionality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Neurology & Neurophysiology Center, Vienna, Austria.
- Disciplina de Neurociência, Escola Paulista de Medicina/Universidade Federal de São Paulo/. (EPM/UNIFESP), São Paulo, Brasil.
Zitieren
APA
Finsterer, J., & Scorza, F. A. (2022). Small fiber neuropathy. Acta Neurologica Scandinavica, 145(5), 493-503. https://doi.org/10.1111/ane.13591
Vancouver
Finsterer J, Scorza FA. Small fiber neuropathy. Acta Neurologica Scandinavica. 2022;145(5):493-503. doi:10.1111/ane.13591
BibTeX
@article{Finsterer2022,
author = {Finsterer, Josef and Scorza, Fulvio A},
title = {Small fiber neuropathy},
journal = {Acta Neurologica Scandinavica},
year = {2022},
volume = {145},
number = {5},
pages = {493--503},
doi = {10.1111/ane.13591}
}
EUVIMED